the inhaled insulin experiment looks to be over

inhaled insulin looks dead. pfe and nktr warned of an increased lung cancer risk for diabetics using the inhaled insulin exubera. recall, exubera flopped commercially, leading pfe to stop marketing the product and terminating its partnership with nktr. but nktr was trying to land another partner for the drug; those efforts have now been terminated. clearly, this new safety concern with inhaled insulin is a killer for mnkd as well because it's still trying to develop its own product.